Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Ocera Therapeutics, Inc. (OCRX)
|
Add to portfolio |
|
|
|
| Price: |
$1.79
| | Metrics |
| OS: |
26.5
|
M
| |
-630
|
% ROE
|
| Market cap: |
$47.5
|
M
| |
|
|
|
Net cash:
|
$6.66
|
M
| |
$0.25
|
per share
|
|
EV:
|
$40.8
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($24.1)
|
M
| |
|
|
|
EBIT
|
($24.1)
|
M
| |
|
|
| EPS |
($0.98)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
| Revenues | 0.6 | 0.1 | 0.3 | 0.1 | 0.0 | 10.2 | 8.5 | 0.7 |
| Revenue growth | 357.9% | -61.0% | 301.2% | | -100.0% | 19.1% | 1072.8% | 103.9% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.6 | 0.1 | 0.3 | 0.1 | 0.0 | 10.2 | 8.5 | 0.7 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | | 100.0% | 100.0% | 100.0% |
| Research and development | 16.1 | 16.0 | 14.9 | 3.5 | 1.6 | 24.9 | 10.1 | 7.3 |
| General and administrative | 10.4 | 10.3 | 9.9 | 8.5 | 1.7 | 6.0 | 3.9 | 3.4 |
| EBITA | -26.1 | -26.1 | -23.4 | -14.0 | -3.4 | -20.7 | -5.4 | -10.0 |
| EBITA margin | -4285.4% | -19636.1% | -6876.0% | -16517.6% | | -204.0% | -63.4% | -1371.6% |
| Amortization of intangibles | | 0.2 | 0.2 | 0.3 | | | | |
| EBIT | -26.1 | -26.3 | -23.6 | -14.3 | -3.4 | -20.7 | -5.4 | -10.0 |
| EBIT margin | -4285.4% | -19764.7% | -6924.0% | -16864.7% | | -204.0% | -63.4% | -1371.6% |
| Pre-tax income | -26.9 | -26.5 | -23.4 | -17.5 | -3.6 | -22.2 | -7.3 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net income | -26.9 | -26.5 | -23.4 | -17.5 | -3.6 | -22.2 | -7.3 | -11.2 |
| Net margin | -4416.3% | -19941.4% | -6869.5% | -20604.7% | | -218.4% | -85.5% | -1534.9% |
| |
| Diluted EPS | ($1.22) | ($1.32) | ($1.34) | ($2.85) | ($5.76) | ($1.22) | ($52.07) | ($79.70) |
| Shares outstanding (diluted) | 22.0 | 20.1 | 17.5 | 6.1 | 0.6 | 18.1 | 0.1 | 0.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|